Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Declines in Social Support During Breast Cancer Treatment and Their Association With Exercise Capacity Reductions in Breast Cancer Survivors.

American journal of lifestyle medicine·2026
Same author

Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.

Nature medicine·2026
Same author

Cardiac remodelling and dysfunction in cancer patients receiving cardiotoxic therapies: proteomic and metabolomic profiling.

European heart journal·2026
Same author

Atrial Fibrillation Risk and Cardiovascular Events After Hematopoietic Cell Transplantation: A Prospective Cohort Study.

JACC. CardioOncology·2026
Same author

In Memoriam: Dr Eugene Braunwald, MD, MACC.

JACC. CardioOncology·2026
Same author

Tissue-Resident Memory T Cells in the Heart: An Emerging Role in Chronic Inflammation.

Immunological reviews·2026

Related Experiment Video

Updated: Jun 14, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the

Vlad G Zaha, Salim S Hayek, Kevin M Alexander

    Circulation
    |November 10, 2021
    PubMed
    Summary

    Precision medicine improves cancer survival, making cardiovascular health crucial. This statement explores integrating biomarkers, imaging, and data for personalized cardio-oncology, addressing current gaps in cardiovascular risk assessment and monitoring during cancer treatment.

    Keywords:
    AHA Scientific Statementsbiomarkerscancer survivorscardiologyoncologyprecision medicine

    More Related Videos

    Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
    10:03

    Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

    Published on: January 28, 2020

    Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
    07:25

    Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

    Published on: September 22, 2020

    Related Experiment Videos

    Last Updated: Jun 14, 2026

    Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
    14:24

    Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

    Published on: January 21, 2018

    Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
    10:03

    Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

    Published on: January 28, 2020

    Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
    07:25

    Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

    Published on: September 22, 2020

    Area of Science:

    • Cardio-oncology
    • Biomarker discovery
    • Precision medicine

    Background:

    • Cancer survival has improved due to precision medicine and immunotherapies.
    • Cardiovascular health is now a critical factor in overall cancer patient outcomes.
    • Traditional tissue diagnostics are central to cancer care but limited in cardio-oncology.

    Purpose of the Study:

    • To explore a systemic approach for cardiovascular tissue diagnosis in cardio-oncology.
    • To personalize this approach for diverse clinical scenarios in cardio-oncology.
    • To address limitations and knowledge gaps in current cardiovascular biomarker applications.

    Main Methods:

    • Literature review on established cardiovascular biomarkers in cancer patients.
    • Exploration of integrating circulating biomarkers, multimodality imaging, panomics, and digital physiological data.
    • Broad definition of the biomarker concept for cardio-oncology.

    Main Results:

    • Identified limitations and knowledge gaps in cardiovascular biomarker use for risk stratification, monitoring, and damage detection.
    • Summarized current literature on cardiovascular biomarkers at the cancer intersection.
    • Highlighted the need for a systemic, personalized approach in cardio-oncology.

    Conclusions:

    • A systemic approach integrating diverse data streams is proposed to overcome challenges in cardio-oncology diagnosis.
    • Personalization of this approach is key for diverse patient populations, cancer types, and therapies.
    • Concerted efforts in biomarker discovery, validation, and clinical application are needed at the cardio-oncology nexus.